Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

3.70USD
23 May 2018
Change (% chg)

$-0.03 (-0.80%)
Prev Close
$3.73
Open
$3.71
Day's High
$3.77
Day's Low
$3.67
Volume
32,840
Avg. Vol
139,932
52-wk High
$7.94
52-wk Low
$3.23

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2B POLT-HCV SVR CLINICAL TRIAL.THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT IN HETEROGENEOUS OVERALL TRIAL POPULATION.BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION.CONATUS PHARMACEUTICALS INC - ENCORE-NF FOR NASH FIBROSIS TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019.CONATUS PHARMACEUTICALS INC - ENCORE-LF FOR LIVER FUNCTION WITH TOP-LINE RESULTS EXPECTED IN SECOND HALF OF 2019.  Full Article

Conatus Pharmaceuticals reports Q3 revenue of $9.6 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates.Q3 revenue $9.6 million.Q3 revenue view $16.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals Inc - qtrly ‍net loss per share $0.13.  Full Article

EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - Conatus Pharmaceuticals Inc :EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC.Conatus Pharmaceuticals - ‍continue to evaluate potential internal, external opportunities with goal of announcing initial pipeline expansion plans later in 2017​.  Full Article

Conatus Pharmaceuticals Inc qtrly loss per share $0.30
Wednesday, 3 Aug 2016 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports second quarter 2016 financial results and program updates . Conatus pharmaceuticals inc qtrly loss per share $0.30 .Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Conatus Pharmaceuticals Q1 Revenue $9.7 Million

* CONATUS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROGRAM UPDATES